FOR INVESTORS

ProtoKinetix has formulated a proprietary anti-aging glycopeptide with the power to change lives through cell survival. The potential is endless, and we’ve only seen the tip of the iceberg.

  • Discovery

    Discovery

    2002
    Dr. Geraldine Castelot-Deliencourt invented AAGP® to be a smaller, more stable synthetic version of naturally occurring anti-freeze glycopeptides (AFGPs).
  • Patenting

    Patenting

    2004 to 2017
    ProtoKinetix filed patents for the use of AAGP® in clinical studies, including biologic material preservation, cryosurgery, pancreatic cell health and neurosensory precursor cell survival.
  • Research

    Research

    2016 to present
    A team of the world’s top scientists have studied AAGP®’s effectiveness in cell cryopreservation, monoclonal antibody production and retinal cell replacement over time.
  • Results

    Results

    2016 to present
    Compared to control groups, pluripotent stem cells treated with AAGP® were 300% more viable when transplanted into retinal tissue and matured to the five-month milestone without compromise.

Invest in the future

If you could help find the cure for chronic conditions that affect our lives, what would that be worth to you? An investment in ProtoKinetix is an investment in your financial future and the future of health care. AAGP® can be used in multi-billion-dollar applications and has the potential to touch millions of lives – starting with yours.

Ophthalmology

Researchers believe AAGP® can lead to a future where some causes of blindness can be overcome. In recent clinical studies, AAGP® has been shown to successfully prevent ocular inflammation and greatly improve the success rate of retinal cell replacement , which can ultimately restore vision in many cases. These benefits can also be translated to the prescription market for eye conditions and protection.
2025 Market Forecast:
$35.7 Billion

Potential applications:

  • Chronic dry eye disease
  • Diabetic retinopathy
  • Macular degeneration
  • Sjogren’s syndrome
  • Uveitis

Dermatology

AAGP® works as a dual agent to protect and recover skin from ultraviolet (UV) radiation, harsh chemicals and atopic dermatitis. For the millions of individuals who suffer from skin conditions worldwide, AAGP® could help prevent burns, inflammation, scarring, signs of aging and more.
2025 Market Forecast:
$183 Billion

Potential applications:

  • Cosmetics
  • Eczema
  • Rosacea
  • Sun burn treatments
  • Sunscreen and lip balm

Transplants

AAGP® can help to improve transplant success rates through increased cell survival by reducing or eliminating cell stress and inflammation caused by transplantation. It has been shown to successfully protect various cell types used in regenerative medicine and has potential to benefit whole organ transplantation.
2025 Market Forecast:
$51 Billion

Potential applications:

  • Beta cells for Type 1 diabetes
  • Blood stem cells for cancer
  • Cartilage for arthritis
  • Heart, liver or kidney transplants
  • Retinal grafts for blindness

Biomanufacturing

AAGP® helps to preserve cell viability during cryostorage and biologic production. It could increase production yields of therapeutic antibodies used in immunotherapy treatments for cancer, autoimmune diseases, infections and other disorders. This could make biologics more accessible to the world.
2025 Market Forecast:

$218 Billion

Potential applications:

  • Antibody production
  • Cancer immunotherapy
  • Cartilage for arthritis
  • Cryorecovery
  • Cell transplants

Ready to invest or just want to talk?

Stock information

Investor testimonials

Create a secure online account

Find answers in our investor FAQ

Documentation

We are a debt-free company on solid financial footing. Review our recent SEC filings to see our current financial information.
See our Section 16 Reports to review recent filings by our beneficial owners and principal stockholders.
Download our XBRL Files to review relevant company information and financial statements.

Join us on our journey of cell survival

Get company news and research updates sent directly to your inbox.

Ready to invest?

Reach out and let’s talk about how we can help each other.

Investor Graph
Investor Graph